These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38834228)

  • 1. Treatment of Bullous Pemphigoid With Dupilumab: A Case Series of 30 Patients.
    Miller AC; Temiz LA; Adjei S; Duran MA; Sassmannshausen J; Dominguez A; Thomas C; Schmidt JD; Bernhardt M; Doolittle-Amieva CJ; Moshiri AS; Thompson AJ; Pyoung Kim-Lim P; Mattia AV; Tyring SK
    J Drugs Dermatol; 2024 Jun; 23(6):e144-e148. PubMed ID: 38834228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.
    Zhang Y; Xu Q; Chen L; Chen J; Zhang J; Zou Y; Gong T; Ji C
    Front Immunol; 2021; 12():738907. PubMed ID: 34721404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series.
    Abdat R; Waldman RA; de Bedout V; Czernik A; Mcleod M; King B; Gordon S; Ahmed R; Nichols A; Rothe M; Rosmarin D
    J Am Acad Dermatol; 2020 Jul; 83(1):46-52. PubMed ID: 32179082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab for bullous pemphigoid with intractable pruritus.
    Seidman JS; Eichenfield DZ; Orme CM
    Dermatol Online J; 2019 Nov; 25(11):. PubMed ID: 32045153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The treatment of refractory atypical bullous pemphigoid with generalized eczema and intense pruritus with dupilumab.
    Li W; Cai S; Man X
    Dermatol Ther; 2022 Feb; 35(2):e15243. PubMed ID: 34854196
    [No Abstract]   [Full Text] [Related]  

  • 6. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT.
    Murrell DF; Joly P; Werth VP; Ujiie H; Worm M; Mangold AR; Avetisova E; Maloney J; Laws E; Mortensen E; Dubost-Brama A; Shabbir A
    Adv Ther; 2024 Jul; 41(7):2991-3002. PubMed ID: 38443648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid.
    Seyed Jafari SM; Feldmeyer L; Bossart S; Simon D; Schlapbach C; Borradori L
    Front Immunol; 2020; 11():611549. PubMed ID: 33584689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid.
    Yang J; Gao H; Zhang Z; Tang C; Chen Z; Wang L; Yang F; Chen S; He S; Liu S; Tang L; Xu Y; Hu Y; Ma L; Zhao Y; Luo X
    Dermatol Ther; 2022 Aug; 35(8):e15648. PubMed ID: 35715972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erythrodermic Bullous Pemphigoid in Skin of Color Treated With Dupilumab.
    Sanfilippo E; Gonzalez Lopez A; Saardi KM
    J Drugs Dermatol; 2023 Jul; 22(7):685-686. PubMed ID: 37410035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: Dupilumab for the treatment of bullous pemphigoid.
    Wang M; Wang J; Shi B
    Dermatol Ther; 2022 Jul; 35(7):e15541. PubMed ID: 35478478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study.
    Hu L; Huang R; Jiang F; You S; Wu Q
    Immun Inflamm Dis; 2023 Jul; 11(7):e924. PubMed ID: 37506153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Dupilumab in Patients With Bullous Pemphigoid.
    Zhao L; Wang Q; Liang G; Zhou Y; Yiu N; Yang B; Zhang G; Li W; Feng S; Shang P; Chen X; Zhu X; Zheng J; Pan M; Wang M
    JAMA Dermatol; 2023 Sep; 159(9):953-960. PubMed ID: 37531116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review.
    Liang J; Abulikemu K; Maolidan ; Hu F; Zhao J; Qiu Y; Wang Q; Sang Y; Hong Y; Kang X
    Int Immunopharmacol; 2023 Mar; 116():109788. PubMed ID: 36731156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature.
    Klepper EM; Robinson HN
    Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study.
    Huang D; Zhang Y; Yu Y; Jiang Y; Kong L; Ding Y; Shi Y; Gao Y
    Int Immunopharmacol; 2023 Dec; 125(Pt A):111157. PubMed ID: 37925949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of patients with bullous pemphigoid: comparison of classic bullous pemphigoid to non-bullous pemphigoid.
    Ben Mordehai Y; Faibish H; Astman N; Greenberger S; Barzilai A; Baum S
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):161-165. PubMed ID: 31423677
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term treatment outcomes and safety of dupilumab as a therapy for bullous pemphigoid: A multicenter retrospective review.
    Learned C; Cohen SR; Cunningham K; Alsukait S; Santiago S; Lu J; Rothe M; Nichols A; Rosmarin D
    J Am Acad Dermatol; 2023 Aug; 89(2):378-382. PubMed ID: 37115111
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-interleukin 4 receptor α antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: a monocentric real-world study.
    Wang SH; Shan Y; Li SZ; Zuo YG
    Front Immunol; 2023; 14():1165106. PubMed ID: 37545503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum inflammatory biomarkers associated with disease severity and response to dupilumab treatment in bullous pemphigoid: A cluster analysis.
    Li J; Chen X; Zhu X; Shang P; Wang M
    J Dermatol Sci; 2024 Oct; 116(1):24-33. PubMed ID: 39358056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter.
    Zhang Y; Zhang J; Chen J; Lin M; Gong T; Cheng B; Ji C
    Australas J Dermatol; 2021 Nov; 62(4):525-527. PubMed ID: 34448201
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.